Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of GSK525762 in NUT midline carcinoma and other cancers completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Midline
• Nut Carcinoma
• Nut Midline Carcinomas

Drugs mentioned

• GSK525762

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Midline | Phase 1 | Status: COMPLETED | Results posted: 2020-03-16